{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T10:30:17Z","timestamp":1760783417843},"reference-count":25,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T00:00:00Z","timestamp":1314835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2011,9]]},"DOI":"10.1016\/j.antiviral.2011.06.010","type":"journal-article","created":{"date-parts":[[2011,6,26]],"date-time":"2011-06-26T10:28:35Z","timestamp":1309084115000},"page":"288-291","source":"Crossref","is-referenced-by-count":12,"title":["Characterization of the binding affinities of peramivir and oseltamivir carboxylate to the neuraminidase enzyme"],"prefix":"10.1016","volume":"91","author":[{"given":"Shanta","family":"Bantia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramanda","family":"Upshaw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.S.","family":"Babu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2011.06.010_b0005","doi-asserted-by":"crossref","first-page":"3482","DOI":"10.1021\/jm0002679","article-title":"BCX-1812 (RWJ-270201): discovery of a novel, highly potent, orally active, and selective influenza neuraminidase inhibitor through structure-based drug design","volume":"43","author":"Babu","year":"2000","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2011.06.010_b0010","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1128\/AAC.45.4.1162-1167.2001","article-title":"Comparison of the anti-influenza virus activity of RWJ-270201 with those of oseltamivir and zanamivir","volume":"45","author":"Bantia","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2011.06.010_b0015","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.antiviral.2005.10.002","article-title":"Anti-influenza virus activity of peramivir in mice with single intramuscular injection","volume":"69","author":"Bantia","year":"2006","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2011.06.010_b0020","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.antiviral.2010.09.020","article-title":"Combination of peramivir and rimantadine demonstrate synergistic antiviral effects in sub-lethal influenza A (H3N2) virus mouse model","volume":"88","author":"Bantia","year":"2010","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2011.06.010_b0025","first-page":"44","article-title":"High levels of adamantine resistance among influenza A (H3N2) viruses and interim guidelines for use of antiviral agents\u2014United States, 2005\u20136 influenza season","volume":"55","author":"Bright","year":"2006","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"10.1016\/j.antiviral.2011.06.010_b0030","doi-asserted-by":"crossref","first-page":"2998","DOI":"10.1021\/jm100078r","article-title":"Complexity in influenza virus targeted drug design: interaction with human sialidases","volume":"53","author":"Chavas","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2011.06.010_b0035","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1086\/518936","article-title":"Surveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide","volume":"196","author":"Deyde","year":"2007","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2011.06.010_b0040","doi-asserted-by":"crossref","first-page":"e1000362","DOI":"10.1371\/journal.pmed.1000362","article-title":"Efficacy of oseltamivir\u2013zanamivir combination compared to each monotherapy for seasonal influenza: a randomized placebo-controlled trial","volume":"7","author":"Duval","year":"2010","journal-title":"PLoS Med."},{"key":"10.1016\/j.antiviral.2011.06.010_b0045","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1177\/095632020601700502","article-title":"Rimantadine and oseltamivir demonstrate synergistic combination effect in an experimental infection with type A (H3N2) influenza virus in mice","volume":"17","author":"Galabov","year":"2006","journal-title":"Antivir. Chem. Chemother."},{"key":"10.1016\/j.antiviral.2011.06.010_b0050","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.1128\/AAC.45.10.2723-2732.2001","article-title":"Comparison of efficacies of RWJ-270201, zanamivir, and oseltamivir against H5N1, H9N2, and other avian influenza viruses","volume":"45","author":"Govorkova","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2011.06.010_b0055","doi-asserted-by":"crossref","first-page":"4855","DOI":"10.1128\/AAC.48.12.4855-4863.2004","article-title":"Neuraminidase inhibitor\u2013rimantadine combinations exert additive and synergistic anti-influenza virus effects in MDCK cells","volume":"48","author":"Govorkova","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2011.06.010_b0060","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1056\/NEJM199910283411802","article-title":"Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza","volume":"341","author":"Hayden","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2011.06.010_b0065","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1093\/cid\/cir001","article-title":"Clinical experience in adults and children treated with intravenous peramivir for 2009 influenza A(H1N1) under an emergency IND program in the United States","volume":"52","author":"Hernandez","year":"2011","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2011.06.010_b0070","doi-asserted-by":"crossref","first-page":"10366","DOI":"10.1128\/JVI.01200-09","article-title":"Zanamivir-resistant influenza viruses with a novel neuraminidase mutation","volume":"83","author":"Hurt","year":"2009","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2011.06.010_b0075","unstructured":"Ison, M.G., McGeer, A.J., Hui, D.S., Clezy, K., O\u2019Neil, B., Flynt, A., Elder, J., Simon, T.J., Alexander, W.J., 2009. Safety and efficacy of multiple-day treatment with intravenous peramivir or oral oseltamivir in hospitalized adults with acute influenza. In: XI International Symposium on Respiratory Viral Infections, Bangkok, February 19\u201322, 2009 (Abstract V-6)."},{"key":"10.1016\/j.antiviral.2011.06.010_b0080","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.antiviral.2006.01.012","article-title":"Combination chemotherapy, a potential strategy for reducing the emergence of drug-resistant influenza A variants","volume":"70","author":"Ilyushina","year":"2006","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2011.06.010_b0130","first-page":"CD001169","article-title":"Amantadine and rimantadine for influenza A in adults","volume":"2","author":"Jefferson","year":"2006","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.antiviral.2011.06.010_b0090","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1001\/archinte.163.14.1667","article-title":"Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations","volume":"163","author":"Kaiser","year":"2003","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.antiviral.2011.06.010_b0095","unstructured":"Kohno, S., Yen, M.Y., Cheong, H.J., Hirotsu, N., Ishida, T., Kadota, J., Shimada, J., 2009. Single-intravenous peramivir vs. oral oseltamivir to treat acute, uncomplicated influenza in the outpatient setting: a phase III, randomized, double-blind trial. In: 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2009), San Francisco, September 12\u201315, 2009 (Abstract V-537-a)."},{"key":"10.1016\/j.antiviral.2011.06.010_b0100","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1128\/AAC.42.3.640","article-title":"Oral administration of a prodrug of the influenza virus neuraminidase inhibitor GS 4071 protects mice and ferrets against influenza infection","volume":"42","author":"Mendel","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2011.06.010_b0105","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1056\/NEJMp0900648","article-title":"Global transmission of oseltamivir-resistant influenza","volume":"360","author":"Moscona","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2011.06.010_b0110","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.virol.2009.03.026","article-title":"The origin and global emergence of adamantane resistant A\/H3N2 influenza viruses","volume":"388","author":"Nelson","year":"2009","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2011.06.010_b0115","doi-asserted-by":"crossref","first-page":"e9332","DOI":"10.1371\/journal.pone.0009332","article-title":"Triple combination of amantadine, ribavirin, and oseltamivir is highly active and synergistic against drug resistant influenza virus strains in vitro","volume":"5","author":"Nguyen","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.antiviral.2011.06.010_b0120","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.antiviral.2010.07.003","article-title":"Combinations of oseltamivir and peramivir for the treatment of influenza A (H1N1) virus infections in cell culture and in mice","volume":"88","author":"Smee","year":"2010","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2011.06.010_b0125","unstructured":"Sorbello, A., Jones, S.C., Carter, W., Struble, K., the Peramivir Safety Team, 2010. Safety of peramivir assessed under the FDA emergency use authorization (EUA) to treat hospitalized patients infected with 2009 H1N1 influenza virus. In: 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2010), Boston, September 13\u201316, 2010 (Abstract V-648)."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354211003524?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354211003524?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,12]],"date-time":"2019-06-12T10:39:02Z","timestamp":1560335942000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354211003524"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,9]]}},"alternative-id":["S0166354211003524"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2011.06.010","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2011,9]]}}}